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Background
APOBEC3G (A3G) is an intracellular anti-viral factor
which deaminates cytidine to uridine. The activity of A3G
is countered by Vif, which protects the virus by preventing
incorporation of A3G into virions. A3G can be upregu-
lated  in vitro and  in vivo to overcome Vif activity and
inhibit HIV-1 or SIV infection.
Methods
Human CD4+ T cells were separated from PBMC of nor-
mal HIV-1- subjects and allostimulated by unmatched
irradiated PBMC. A3G was assayed before and after allo-
stimulation by RT-PCR, Western blots and immunofluo-
rescence with A3G-specific antibodies. A3G expression in
the subsets of memory CD4+ T cells was determined by
immunofluorescence with antibodies to A3G, CD45RA
and CCR7. Allo-immunization with recombinant HLA-
class I and class II dextramers, HIVgp140, SIVp27 and the
co-adjuvants HSP70 and Titermax (SC x4) was carried out
in rhesus monkeys and they were challenged with
SHIVSF162.P4.
Results
Allogeneic stimulation of human CD4+ T cells in vitro
upregulated A3G mRNA (p = 0.01). The mechanism of
upregulation of A3G mRNA involves interaction between
HLA on DC and TCR of CD4+ T cells, which is ZAP70
phosphokinase signalling dependent and induces CD40L
and A3G mRNA expression in CD4+ T cells (p = 0.001).
In vivo significant inhibition in viral load or preventing
infection was found against the heterologous viral chal-
lenge, when compared with unimmunized control ani-
mals. A significant increase in A3G mRNA was found
already after the 1st immunization (p < 0.02), with upreg-
ulation of CD4+CD95+CCR7+ central memory T cells.
Conclusion
In vitro allo-stimulation of human CD4+ T cells and in
vivo immunization with recombinant HLA-class I and II
dextramers, trimeric HIVgp140, SIVp27, HSP70 and Titer-
max elicited significant upregulation of A3G in CD4+
memory T cells. A significant inverse correlation between
the cumulative viral load and A3G in the central memory
T cells suggests that A3G may have contributed to the pre-
vention of SHIV SF162.P4 infection.
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